Business Description
Avadel Pharmaceuticals PLC
NAICS : 325414
SIC : 2834
ISIN : IE00BDGMC594
Share Class Description:
AVDL: ADRDescription
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 40.06 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5 | |||||
| 3-Year EPS without NRI Growth Rate | -63.8 | |||||
| 3-Year FCF Growth Rate | -21.7 | |||||
| 3-Year Book Growth Rate | -29.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.28 | |||||
| 9-Day RSI | 60.15 | |||||
| 14-Day RSI | 59.8 | |||||
| 6-1 Month Momentum % | 67.42 | |||||
| 12-1 Month Momentum % | 61.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.64 | |||||
| Quick Ratio | 3.36 | |||||
| Cash Ratio | 2.85 | |||||
| Days Inventory | 2459.94 | |||||
| Days Sales Outstanding | 87.53 | |||||
| Days Payable | 4693.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.4 | |||||
| Shareholder Yield % | -3.05 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.98 | |||||
| Operating Margin % | -492.97 | |||||
| Net Margin % | -573.17 | |||||
| FCF Margin % | -459.58 | |||||
| ROE % | -284.41 | |||||
| ROA % | -95.14 | |||||
| ROIC % | -211.06 | |||||
| ROC (Joel Greenblatt) % | -1173.85 | |||||
| ROCE % | -133.59 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 56.9 | |||||
| PB Ratio | 18.25 | |||||
| Price-to-Tangible-Book | 22.54 | |||||
| EV-to-EBIT | -10.01 | |||||
| EV-to-Forward-EBIT | 96.6 | |||||
| EV-to-EBITDA | -10.13 | |||||
| EV-to-Forward-EBITDA | 1210.53 | |||||
| EV-to-Revenue | 54.03 | |||||
| EV-to-Forward-Revenue | 9.01 | |||||
| EV-to-FCF | -11.76 | |||||
| Price-to-Net-Current-Asset-Value | 27.83 | |||||
| Price-to-Net-Cash | 57.45 | |||||
| Earnings Yield (Greenblatt) % | -9.99 | |||||
| FCF Yield % | -7.97 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers